__timestamp | AbbVie Inc. |
---|---|
Tuesday, January 1, 2019 | 131127740000.00002 |
Wednesday, January 1, 2020 | 178619050000 |
Friday, January 1, 2021 | 239658000000 |
Saturday, January 1, 2022 | 286211310000 |
Sunday, January 1, 2023 | 273986960000 |
Infusing magic into the data realm
Over the past five years, AbbVie Inc. has demonstrated a remarkable trend in its market capitalization, reflecting its robust financial health and strategic growth. From 2019 to 2023, AbbVie's market cap surged by approximately 109%, starting at $131 billion in 2019 and peaking at $286 billion in 2022. This impressive growth trajectory underscores AbbVie's resilience and adaptability in a dynamic market environment.
This data highlights AbbVie's strategic initiatives and market confidence. The slight dip in 2023 could be attributed to market corrections or strategic reinvestments. Investors and stakeholders can glean valuable insights from this trend, emphasizing the importance of long-term investment strategies in the pharmaceutical sector.
5 Year Trend in Average Market Capitalization for AbbVie
Annual Comparison of SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline
Average Market Capitalization of Abbvie Annually
Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
Comparison of Average SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline Over the Years
Comparison of Average SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline Over the Years
Number of Employees for Top 10 Pharma Companies
5 Year Trend in Average Market Capitalization for AbbVie
5 Year Trend in Market Capitalization for AbbVie
Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
Number of Employees for Top 10 Healthcare Companies
Comparison of Net Income Margin for Glaxosmithkline, AstraZeneca, Takeda, and Eli Lilly Over the Last 8 Quarters